Barinthus Biotherapeutics plc
BRNS
$0.73
$0.011.54%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 14.97M | 14.97M | 14.97M | 14.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 14.97M | 14.97M | 14.97M | 14.97M |
| Cost of Revenue | 13.25M | 18.95M | 19.45M | 22.23M | 22.78M |
| Gross Profit | -13.25M | -3.98M | -4.49M | -7.27M | -7.81M |
| SG&A Expenses | 30.30M | 39.00M | 30.82M | 24.23M | 41.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -298.00K | -226.00K | -790.00K | -766.00K | -582.00K |
| Total Operating Expenses | 55.47M | 69.58M | 65.19M | 61.11M | 77.91M |
| Operating Income | -55.47M | -54.61M | -50.22M | -46.14M | -62.94M |
| Income Before Tax | -76.06M | -69.55M | -65.35M | -61.23M | -58.75M |
| Income Tax Expenses | -115.00K | -47.00K | -29.00K | -44.00K | -867.00K |
| Earnings from Continuing Operations | -75.95 | -69.50 | -65.32 | -61.18 | -57.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 68.00K | 78.00K | 88.00K | 109.00K | 55.00K |
| Net Income | -75.88M | -69.43M | -65.23M | -61.07M | -57.83M |
| EBIT | -55.47M | -54.61M | -50.22M | -46.14M | -62.94M |
| EBITDA | -52.31M | -50.87M | -47.01M | -43.54M | -60.33M |
| EPS Basic | -1.88 | -1.73 | -1.64 | -1.55 | -1.49 |
| Normalized Basic EPS | -0.82 | -0.80 | -0.75 | -0.69 | -0.96 |
| EPS Diluted | -1.89 | -1.74 | -1.65 | -1.56 | -1.49 |
| Normalized Diluted EPS | -0.82 | -0.80 | -0.75 | -0.69 | -0.96 |
| Average Basic Shares Outstanding | 161.43M | 160.18M | 158.88M | 157.39M | 155.82M |
| Average Diluted Shares Outstanding | 161.43M | 160.18M | 158.88M | 157.39M | 155.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |